Delving into the Latest Updates on Recombinant alkaline phosphatase(AM-Pharma Holding BV) with Synapse

Overview

Basic Info

Drug Type

Enzyme

Synonyms

Human recombinant alkaline phosphatase, Recombinant alkaline phosphatase, Recombinant optimised human alkaline phosphatase

+ [1]

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesUrogenital DiseasesOther Diseases

Active Indication-

Inactive Indication

Acute Kidney InjurySepsis

Originator Organization

AM-Pharma Holding BV

Active Organization-

Inactive Organization

AM-Pharma Holding BV

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Sepsis, broadly described as a systemic infection, is one of the leading causes of death and long-term disability worldwide. There are limited therapeutic options available that either improve survival and/or improve the quality of life in survivors. Ilofotase alfa, also known as recombinant alkaline phosphatase (recAP), has been associated with reduced mortality in a subset of patients with sepsis-associated acute kidney injury. However, whether recAP exhibits any therapeutic benefits in other organ systems beyond the kidney is less clear. The objective of this study was to evaluate the effects of recAP on survival, behavior, and intestinal inflammation in a mouse model of sepsis, cecal ligation and puncture (CLP). Following CLP, either recAP or saline vehicle was administered via daily intraperitoneal injections to determine its treatment efficacy from early through late sepsis. We found that administration of recAP suppressed indices of inflammation in the gut and liver but did not improve survival or behavioral outcomes. These results demonstrate that recAP's therapeutic efficacy in the gut and liver may provide a valuable treatment to improve long-term outcomes in sepsis survivors.

01 Jan 2024·Intensive Care Medicine

Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)

Article

Author: Dey, Nilanjan ; Vinsonneau, Christophe ; McGuinness, Shay ; Winkel, Matthias ; Kamper, Maj ; Gammelager, Hendrik ; Gomez, Hernando ; Solling, Christoffer ; Kluge, Stefan ; Wood, Gordon ; Mosier, Jarrod ; Lefrant, Jean Yves ; Nichol, Alistair ; Fivez, Tom ; Lemarie, Jermie ; van den Berg, Erik ; Tsuruoka, Ayumu ; Gibot, Sebastien ; Liu, Kathleen ; Pedersen, Ulf Goettrup ; Busse, Larry ; McNicolas, Bairbre ; Meziani, Ferhat ; Mercier, Emmanuelle ; Van Zanten, Arthur ; Hite, Duncan ; Strøm, Thomas ; Doi, Kent ; Martin-Loeches, Ignatio ; Francois, Bruno ; Kamohara, Hidenobu ; Gérard, Ludovic ; Dormans, Tom ; Beishuizen, Bert ; Doig, Chistopher J. ; Muller, Gregoire ; Huberlant, Vincent ; Rasmussen, Bodil Steen ; Iversen, Susanne ; Valkonen, Mila ; Monnet, Xavier ; Mizushima, Yasuaki ; Boldt, David ; Iversen, Sussanne ; Doig, Christopher ; Waddy, Sam ; Joannidis, Michael ; Bernard, Andrew ; Bachoumas, Konstantimos ; Furuya, Ryo ; Tuinman, Pieter ; Bestle, Morten H. ; Groefte, Thorbjoern ; Fries, Dietmar ; Exline, Matthew ; Meersch, Melanie ; Young, Paul ; Bernholz, Juliane ; Pettilä, Ville ; Quenot, Jean-Pierre ; Honore, Patrick M. ; Plantefeve, Gaetan ; Roca, Ricard Ferrer ; Marx, Gernot ; Millington, Scott ; Fichtner, Sebastian ; Turgeon, Alexis ; Nielsen, Nathan ; Bass, Kristie ; Murugan, Raghaven ; Margolis, Benjamin ; Nakagami, Takuo ; Young, Paul J. ; Wise, Matt ; Cardenas, Carol Lorencio ; Ostermann, Marlies ; Fedou, Anne-Laure ; Zamora, Felix ; Wim Roozendaal, F ; Mehta, Ravindra ; Twardowski, Pawel ; Perez, Anna Navas ; Adachi, Shingo ; Jalkanen, Ville ; Boyd, John ; Angus, Derek C. ; Zarbock, Alexander ; Hoste, Eric ; DeSchryver, Nicolas ; Davison, Danielle ; McArthur, Colin ; Kellum, John A. ; MacCallum, Niall ; Pickkers, Peter ; Carter, Angus ; Sølling, Christoffer Grant ; Truwit, Jonathon ; Guitton, Christophe ; Kortgen, Andreas ; Files, Daniel ; Pedersen, Ulf Gøttrup ; Sagasti, Fernando Martinez ; Gammelager, Henrik ; Asfar, Pierre ; Ota, Kohei ; Mebazaa, Alexandre ; Welters, Ingeborg ; Ferrer, Ricard ; Hoiting, Oscar ; Michaux, Isabelle ; Murray, Patrick T. ; Harada, Masahiro ; Inoue, Satoki ; Bellomo, Rinaldo ; Eller, Philip ; Williams, Anthony ; Dufour, Jean Louis ; Uusalo, Panu ; Mæller, Morten Hyllander ; Diltoer, Elisabeth

PURPOSEIlofotase alfa is a human recombinant alkaline phosphatase with reno-protective effects that showed improved survival and reduced Major Adverse Kidney Events by 90 days (MAKE90) in sepsis-associated acute kidney injury (SA-AKI) patients. REVIVAL, was a phase-3 trial conducted to confirm its efficacy and safety.METHODSIn this international double-blinded randomized-controlled trial, SA-AKI patients were enrolled < 72 h on vasopressor and < 24 h of AKI. The primary endpoint was 28-day all-cause mortality. The main secondary endpoint was MAKE90, other secondary endpoints were (i) days alive and free of organ support through day 28, (ii) days alive and out of the intensive care unit (ICU) through day 28, and (iii) time to death through day 90. Prior to unblinding, the statistical analysis plan was amended, including an updated MAKE90 definition.RESULTSSix hundred fifty patients were treated and analyzed for safety; and 649 for efficacy data (ilofotase alfa n = 330; placebo n = 319). The observed mortality rates in the ilofotase alfa and placebo groups were 27.9% and 27.9% at 28 days, and 33.9% and 34.8% at 90 days. The trial was stopped for futility on the primary endpoint. The observed proportion of patients with MAKE90A and MAKE90B were 56.7% and 37.4% in the ilofotase alfa group vs. 64.6% and 42.8% in the placebo group. Median [interquartile range (IQR)] days alive and free of organ support were 17 [0-24] and 14 [0-24], number of days alive and discharged from the ICU through day 28 were 15 [0-22] and 10 [0-22] in the ilofotase alfa and placebo groups, respectively. Adverse events were reported in 67.9% and 75% patients in the ilofotase and placebo group.CONCLUSIONAmong critically ill patients with SA-AKI, ilofotase alfa did not improve day 28 survival. There may, however, be reduced MAKE90 events. No safety concerns were identified.

14 Mar 2022·Cureus

Not Your Typical Bisphosphonate Intolerance: A Case of Unusual Bone Pain With Low Alkaline Phosphatase

Author: Markert, Ronald J ; Bickford, Brant W ; Bennett, Sonia

Bisphosphonates, first-line medications for osteoporosis, are often not tolerated or discontinued for multiple reasons. Hypophosphatasia (HPP) is a genetic deficiency with the enzyme activity of tissue-nonspecific alkaline phosphatase (TNSALP). The symptoms of adult HPP are often non-specific, and the diagnosis may be delayed for years. Low serum alkaline phosphatase, a hallmark feature of HPP, is often overlooked. Genetic testing is recommended to confirm diagnosis, and treatment with asfotase alfa, a recombinant alkaline phosphatase, is available for patients with HPP. We report a case of HPP in a 71-year-old female with recurrent skeletal pain and bisphosphonate intolerance who ultimately was diagnosed with HPP.

100 Deals associated with Recombinant alkaline phosphatase(AM-Pharma Holding BV)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Kidney Injury	Phase 2	FR	AM-Pharma Holding BV	18 Dec 2014
Acute Kidney Injury	Phase 2	BE	AM-Pharma Holding BV	18 Dec 2014
Acute Kidney Injury	Phase 2	NL	AM-Pharma Holding BV	18 Dec 2014
Acute Kidney Injury	Phase 2	CZ	AM-Pharma Holding BV	18 Dec 2014
Acute Kidney Injury	Phase 2	ES	AM-Pharma Holding BV	18 Dec 2014
Acute Kidney Injury	Phase 2	GB	AM-Pharma Holding BV	18 Dec 2014
Acute Kidney Injury	Phase 2	AT	AM-Pharma Holding BV	18 Dec 2014
Acute Kidney Injury	Phase 2	DE	AM-Pharma Holding BV	18 Dec 2014
Acute Kidney Injury	Phase 2	US	AM-Pharma Holding BV	18 Dec 2014
Acute Kidney Injury	Phase 2	FI	AM-Pharma Holding BV	18 Dec 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02182440 (STOP-AKI, CTgov)	Phase 2	Acute Kidney Injury \| Sepsis	301	Placebo (Placebo)	gwcwpajjac(yuhobqrsgp) = mtriixpcej setvddfooz (ybwiqhbqbh, unpwlczcit - jpiqskahgk) View more	-	23 Mar 2020
				recAP (0.4 mg/kg (250 U/kg) recAP)	gwcwpajjac(yuhobqrsgp) = utycfiiqkw setvddfooz (ybwiqhbqbh, kydeihvpbj - bimgcosgag) View more
NCT02182440 (STOP-AKI, Pubmed \| J Coll Physicians Surg Pak)	Phase 2	Acute kidney injury due to sepsis	301	Recombinant Alkaline Phosphatase 0.4 mg/kg	pixcknoczg(wbkaevjrnw) = olnzmawvmy zdmphvxlpu (xxhgnwlbax )	Negative	20 Nov 2018
				Recombinant Alkaline Phosphatase 0.8 mg/kg	pixcknoczg(wbkaevjrnw) = rncrjabuwa zdmphvxlpu (xxhgnwlbax )
phase-II trials (ASN2014)	Phase 2	-	-	Human recombinant Alkaline Phosphatase	pylqmzpxkl(mijvndbvpi) = ewesblcijn erimkmepxi (exuzlrxmrs ) View more	Positive	11 Nov 2014
				Placebo	pylqmzpxkl(mijvndbvpi) = uwfxyomrvh erimkmepxi (exuzlrxmrs ) View more